Classification sets the route
The FDA sorts devices into classes based on risk, and the class largely determines how a device reaches the market. Many lower-risk devices are exempt from premarket review, while many moderate-risk devices reach the market through premarket notification, known as a 510(k), which asks whether the device is substantially equivalent to one already legally marketed. A new device with no suitable comparison may use the De Novo process if its risk is low to moderate. Higher-risk devices generally need premarket approval, which calls for clinical evidence of safety and effectiveness. Medical device approvals in the strict sense refer to that last path, while a 510(k) results in clearance.
Words and evidence that matter
Describing a cleared device as "FDA approved" in marketing is a common mistake and can mislead buyers and regulators alike. The predicate device chosen for a 510(k), the intended use statement, and the testing plan shape the whole submission and are hard to change later. Software and devices that use artificial intelligence raise questions about which features need review and how changes after clearance are handled. Clinical studies of significant-risk devices usually need an investigational device exemption before enrollment begins. Keep design control records from early on, since the agency and later acquirers will expect them.
Planning the submission
We start with what the device does, how it is intended to be used, and which similar products are already on the market. That allows a realistic view of the likely pathway and whether a pre-submission meeting with the FDA would help settle open questions. We also look at how your regulatory plan lines up with financing milestones and with what you are saying publicly. Breakthrough designation and other programs may be available for some devices, and we discuss whether they fit. The aim is a pathway decision you can explain to investors and support before the agency.
